Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Tumors Clear all
Terminated Phase 1Phase 2 Interventional Results available

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

NCT00861471
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Docetaxel, Imatinib Mesylate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting No phase listed Observational

Mechanisms of Resistance to PSMA Radioligand Therapy

NCT05435495
View directory record Official record
Conditions
Prostate Cancer
Interventions
Single-photon emission computed tomography, Blood Draw, Tumor Biopsy
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Terminated Phase 1 Interventional

Study of ORIC-101 in Combination With Enzalutamide

NCT04033328
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
ORIC-101, enzalutamide 40 MG oral capsule [Xtandi]
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
New York, New York • Myrtle Beach, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Not applicable Interventional Results available

Clinical Outcomes for Offering Genetic Testing in a Tiered Approach

NCT04902144
View directory record Official record
Conditions
Breast Carcinoma, Colon Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions
Electronic Health Record Review, Questionnaire Administration, Behavioral Intervention
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sequim, Washington
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting Phase 1 Interventional

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT05613894
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 3 Interventional

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

NCT00002881
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, goserelin acetate, leuprolide acetate, suramin, therapeutic hydrocortisone, orchiectomy
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting No phase listed Observational

A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide

NCT07672119
View directory record Official record
Conditions
Prostate Cancer
Interventions
No intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
55 Years and older · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer

NCT00559429
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2008 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01240629
View directory record Official record
Conditions
Prostate Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
laboratory biomarker analysis, questionnaire administration, doxorubicin-GnRH agonist conjugate AEZS-108
Other · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting Phase 2 Interventional

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

NCT04573231
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Terminated Phase 2 Interventional Results available

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

NCT04951492
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Olaparib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

NCT06457919
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tinengotinib, abiraterone acetate with prednisone, Enzalutamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
New Haven, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Not applicable Interventional

Post-Discharge Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery

NCT03536065
View directory record Official record
Conditions
Prostate Cancer, Opioid Use
Interventions
Opioid Reduction Intervention, Current Care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139

NCT02362464
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasms of Prostate, Prostate Cancer, Cancer Of Prostate, Stage D0 Prostate Cancer
Interventions
Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Not applicable Interventional

A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy

NCT00719030
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pomegranate pill, Pomegranate pill placebo
Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

NCT05059236
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
Darolutamide (BAY1841788, Nubeqa), ADT
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting Not applicable Interventional

Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer

NCT07093177
View directory record Official record
Conditions
Prostate Cancer
Interventions
Telerehabilitation Unit
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting Phase 2 Interventional

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

NCT06734130
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer
Interventions
Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

NCT04503265
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Interventions
AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II
Drug
Lead sponsor
AtlasMedx, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional

Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy

NCT01227642
View directory record Official record
Conditions
Clinical Stage T2b or Less of Prostate Cancer, Prostate Brachytherapy, Transrectal Prostate Ultrasound Treatment Planning
Interventions
An ultrasound-based technique to identify prostate cancer, pre-implant transrectal ultrasound images and planning, ultrasound-based cancer-specific images
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 25, 2026, 8:04 AM EDT
Completed No phase listed Observational

Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer

NCT02425228
View directory record Official record
Conditions
Elevated PSA, Prostate Cancer
Interventions
Targeted biopsy
Device
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

NCT03043807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

NCT00134056
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
atrasentan hydrochloride, docetaxel, prednisone, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
554
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 25, 2026, 8:04 AM EDT
Terminated Not applicable Interventional Results available

Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis

NCT00918645
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
41 Ca
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Livermore, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 25, 2026, 8:04 AM EDT